

**CHEMISTRY AND TECHNOLOGY OF MEDICINAL COMPOUNDS  
AND BIOLOGICALLY ACTIVE SUBSTANCES**  
**ХИМИЯ И ТЕХНОЛОГИЯ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ  
И БИОЛОГИЧЕСКИ АКТИВНЫХ СОЕДИНЕНИЙ**

ISSN 2686-7575 (Online)

<https://doi.org/10.32362/2410-6593-2021-16-2-156-166>



UDC 547.464.7

**RESEARCH ARTICLE**

**Synthesis of ethers containing 1,3-dioxolane  
and *gem*-dichlorocyclopropane fragments**

**Shakhobiddin Sh. Dzhumaev<sup>1</sup>, Yulianna G. Borisova<sup>1,✉</sup>, Gul'nara Z. Raskil'dina<sup>1</sup>,  
Ulyana Sh. Kuzmina<sup>2</sup>, Rustem R. Daminev<sup>3</sup>, Simon S. Zlotskii<sup>1</sup>**

<sup>1</sup>*Ufa State Petroleum Technological University, Ufa, 450062 Russia*

<sup>2</sup>*Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, 450054 Russia*

<sup>3</sup>*Ufa State Petroleum Technological University, Branch in Sterlitamak, Sterlitamak, 453118 Russia*

<sup>✉</sup>*Corresponding author, e-mail: yulianna\_borisova@mail.ru*

**Abstract**

**Objectives.** This study aimed to obtain ethers containing *gem*-dichlorocyclopropane and 1,3-dioxolane fragments and evaluate their cytotoxic properties against HEK293, SH-SY5Y, MCF-7, and A549 cell lines.

**Methods.** The qualitative and quantitative compositions of the reaction masses were determined using mass spectrometry (using a Chromatek-Kristall 5000M device with the 2012 National Institute of Standards and Technology, USA database) and nuclear magnetic resonance spectroscopy (using a Bruker AM-500 device with operating frequencies of 500 and 125 MHz).

**Results.** Ethers containing *gem*-dichlorocyclopropane and 1,3-dioxolane fragments were synthesized in the presence of a catamine AB catalyst. The structures of the obtained substances were confirmed using gas-liquid chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. The cytotoxicity of the esters was studied against HEK293, SH-SY5Y, MCF-7, and A549 cell lines.

**Conclusions.** Ethers containing *gem*-dichlorocyclopropane and 1,3-dioxolane fragments were obtained in quantitative yields; however, only 4-*{[(2,2-dichloro-3-*{[(2,2-dichlorocyclopropyl)methoxy]methyl}cyclopropyl)methoxy]methyl}-2,2-dimethyl-1,3-dioxolane exhibited cytotoxic activity against HEK293, SH-SY5Y, MCF-7, and A549 cell lines.**

**Keywords:** 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane, carbenation, cell lines, cytotoxicity

**For citation:** Dzhumaev Sh.Sh., Borisova Yu.G., Raskil'dina G.Z., Kuzmina U.Sh., Daminev R.R., Zlotskii S.S. Synthesis of ethers containing 1,3-dioxolane and *gem*-dichlorocyclopropane fragments. *Tonk. Khim. Tekhnol. = Fine Chem. Technol.* 2021;16(2):156–166 (Russ., Eng.). <https://doi.org/10.32362/2410-6593-2021-16-2-156-166>

## НАУЧНАЯ СТАТЬЯ

# Синтез простых эфиров, содержащих 1,3-диоксолановый и *гем*-дихлорциклогексановый фрагменты

**Ш.Ш. Джумаев<sup>1</sup>, Ю.Г. Борисова<sup>1@</sup>, Г.З. Раскильдина<sup>1</sup>, У.Ш. Кузьмина<sup>2</sup>,  
Р.Р. Даминев<sup>3</sup>, С.С. Злотский<sup>1</sup>**

<sup>1</sup>Уфимский государственный нефтяной технический университет, Уфа, 450064 Россия

<sup>2</sup>Институт биохимии и генетики УФИЦ РАН, Уфа, 450054 Россия

<sup>3</sup>Уфимский государственный нефтяной технический университет, филиал в г. Стерлитамак, Стерлитамак, 453118 Россия

<sup>@</sup>Автор для переписки, e-mail: [yulianna\\_borisova@mail.ru](mailto:yulianna_borisova@mail.ru)

## Аннотация

**Цели.** Получить простые эфиры, содержащие *гем*-дихлорциклогексановый и 1,3-диоксолановый фрагменты и оценить их цитотоксические свойства в отношении клеточных линий HEK293, SH-SY5Y, MCF-7 и A549.

**Методы.** Для определения качественного и количественного состава реакционных масс были использованы следующие методы анализа: газожидкостная хроматография (на аппаратно-программном комплексе «Кристалл 2000»), масс-спектрометрия (на приборе «Хроматэк-Кристалл 5000М» с базой NIST 2012), и спектроскопия ядерного магнитного резонанса (ЯМР-спектроскопия) (на приборе «Bruker AM-500» с рабочими частотами 500 и 125 МГц).

**Результаты.** Синтезированы простые эфиры, содержащие *гем*-дихлорциклогексановый и 1,3-диоксолановый фрагменты в присутствии катализатора катамина АВ. Строение полученных веществ было подтверждено с помощью газожидкостной хроматографии, масс-спектрометрии и ЯМР-спектроскопии. Для эфиров изучена цитотоксическая активность в отношении клеточных линий HEK293, SH-SY5Y, MCF-7 и A549.

**Выводы.** С количественными выходами получены простые эфиры, содержащие *гем*-дихлорциклогексановый и 1,3-диоксолановый фрагменты. Установлено, что цитотоксическую активность в отношении клеточных линий HEK293, SH-SY5Y, MCF-7 и A549 среди ряда полученных соединений проявляет только 4-*{[(2,2-дихлоро-3-*{[(2,2-дихлорциклогексопропил)метокси]метил}циклогексопропил)метокси]метил}-2,2-диметил-1,3-диоксолан.**

**Ключевые слова:** 2,2-диметил-4-оксиметил-1,3-диоксолан, карбенирование, клеточные линии, цитотоксичность

**Для цитирования:** Джумаев Ш.Ш., Борисова Ю.Г., Раскильдина Г.З., Кузьмина У.Ш., Даминев Р.Р., Злотский С.С. Синтез простых эфиров, содержащих 1,3-диоксолановый и *гем*-дихлорциклогексановый фрагменты. *Тонкие химические технологии.* 2021;16(2):156–166. <https://doi.org/10.32362/2410-6593-2021-16-2-156-166>

## INTRODUCTION

Compounds containing cycloacetal and *gem*-dichlorocyclopropane fragments are important intermediate and final products in the pharmaceutical, perfume, and polymer industries and, depending on the structure of the substituents, exhibit a wide spectrum of biological activity [1–10]. For example, 2-{(4R)-4[(benzyloxy)methyl]-1,3-dioxolan-2-yl}phenol, diisopropyl-(4R-5R)-2-(2-hydroxyphenyl)-1,3-dioxolane-4,5-dicarboxylate, diisopropyl-2-(2-hydroxyphenyl)-1,3-dioxolane-4,5-dicarboxylate, dimethyl 2-(2-hydroxyphenyl)-1,3-dioxolane-4,5-dicarboxylate, and 2-[(4S,5S)-4,5-bis(benzylloxymethyl)-1,3-dioxolane-2-yl]phenol have been shown to exhibit pronounced antibacterial properties against *Staphylococcus aureus* and *Staphylococcus epidermidis* as well as antifungal activity against *Candida albicans* [5].

Özkanlı and co-authors, demonstrated that new derivatives of 2-acetylnaphthalene with the dioxolane structure have an anticonvulsant effect [11]. In addition, it has been shown that 1,3-dioxolane heterocyclic compounds are not only effective anticancer agents but are able to overcome the phenomenon of multidrug resistance, which is one of the main problems in successful cancer therapy [12]. We have previously reported compounds containing 1,3-dioxolane and *gem*-dichlorocyclopropane fragments with potential antitumor activity [3], and these heterocyclic compounds have also been shown to have herbicidal [1], antioxidant [3], antiviral [13, 14], anticoagulant, antiaggregatory [7], and anesthetic [15] activities. This breadth of activities and the fact that many groups are only partially studied means that the synthesis of novel 1,3-dioxolane and *gem*-dichlorocyclopropane fragment-containing compounds is a promising route to finding biologically active substances.

This study aimed to develop new methods for preparing novel bi- and polycyclic compounds, where 1,3-dioxolane and *gem*-dichlorocyclopropane fragments are bound by the stable but mobile CH<sub>2</sub>—O—CH<sub>2</sub> group in acidic and alkaline media, as well as assessing their cytotoxic properties *in vitro*.

## MATERIALS AND METHODS

The analysis of the reaction masses and the recording of the mass spectra of the compounds were carried out on a Chromatec-Kristall 5000M (*CHROMATEC*, Russia) hardware-software complex using the National Institute of Standards and Technology 2012 database (NIST, USA). The analysis conditions were as follows: 30 m long capillary quartz column, 20 min duration, 260°C ion source, 300°C transition line, 30–300 Da scanning range, 37–43 mTorr pressure, helium carrier gas, and a heating rate of 20°C/min. The mass spectra of the compounds were obtained using

electron impact ionization. <sup>1</sup>H and <sup>13</sup>C nuclear magnetic resonance (NMR) spectra were recorded using a Bruker AM-500 spectrometer (*Bruker Corporation*, USA) with operating frequencies of 500 and 125 MHz, respectively, and a CDCl<sub>3</sub> solvent. The chemical shifts were reported on a δ (ppm) scale relative to an internal tetramethylsilane standard. Spin-spin coupling constants (J) were recorded in Hz.

**Synthesis of 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane 1.** A mixture of 0.49 mol of glycerol, 49 mol of acetone, and 0.22 g of *p*-toluenesulfonic acid was vigorously stirred at room temperature for 18 h followed by the addition of 3 g (anhydrous) K<sub>2</sub>CO<sub>3</sub> and stirring for 1 h. The mixture was then filtered, concentrated, and the residue distilled at reduced pressure.

Physicochemical constants corresponded with previously reported data [16–22].

### Synthesis of compounds 4–6, 11, and 15.

Catamin-AB catalyst (0.22 g) and 100 g of 50% NaOH solution were added with vigorous stirring at 50°C (or 30°C for allyl chloride) to a solution of 0.06 mol 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane in 60 mL of benzene. After 2 h, 0.30 mol of the corresponding halogenated derivatives were added dropwise. Upon completion of the reaction, the mixture was washed with water, extracted with ethoxyethane (3 × 30 mL), and dried over anhydrous MgSO<sub>4</sub>. Following the removal of the solvent, the residue was distilled under reduced pressure (a detailed procedure is described in [23]).

According to this method, the following were obtained:

**4-[(Allyloxy)methyl]-2,2-dimethyl-1,3-dioxolane 4.** The NMR spectrum of the compound is given in [24]. Yield (4) 90%, boiling temperature bp = 52–54°C (10 mm Hg). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 172 (≤2) [M]<sup>+</sup>, 157/70, 101/100, 73/25, 55/30.

**4-((2Z)-4-chlorobut-2-en-1-yl)oxy]-methyl)-2,2-dimethyl-1,3-dioxolane 5.** Yield (5) 80%, bp = 81–83°C (5 mm Hg). <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>), δ, ppm (J, Hz): 1.33 t (3H, CH<sub>3</sub>, *J* = 7.0), 1.40 t (3H, CH<sub>3</sub>, *J* = 7.3), 3.44 t (1H, C<sup>6</sup>H<sub>a</sub>, *J* = 9.9, 5.2), 3.51 d (1H, C<sup>6</sup>H<sub>b</sub>, *J* = 10.0, 3.0), 3.70 t (1H, C<sup>5</sup>H<sub>a</sub>, *J* = 8.2, 6.4), 4.03 d (1H, C<sup>5</sup>H<sub>b</sub>, *J* = 8.2, 6.5), 4.09 d (2H, C<sup>7</sup>H<sub>2</sub>, *J* = 11.8, 7.5), 4.14 d (2H, C<sup>10</sup>H<sub>2</sub>, *J* = 11.1, 5.8), 4.22–4.27 m (1H, C<sup>4</sup>H), 5.69–5.81 m (2H, C<sup>8</sup>H, C<sup>9</sup>H). <sup>13</sup>C NMR spectrum (CDCl<sub>3</sub>), δ<sub>c</sub>, ppm: 25.31 (CH<sub>3</sub>), 26.68 (CH<sub>3</sub>), 38.98 (C<sup>10</sup>), 63.88 (C<sup>5</sup>), 66.62 (C<sup>6</sup>), 71.33 (C<sup>7</sup>), 74.65 (C<sup>4</sup>), 109.44 (C<sup>2</sup>), 128.37 (C<sup>8</sup>), 130.53 (C<sup>9</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 220/222 (≤1) [M]<sup>+</sup>, 205/207 (40/15), 115/117 (10/5), 101/100, 89/91 (55/30), 73 (25), 43 (90).

**4,4-[(2Z)-but-2-en-1,4-diyl(oxymethylene)]-bis-(2,2-dimethyl-1,3-dioxolane) 6.** Yield (6) 60%, bp = 101–103°C (3 mm Hg). <sup>1</sup>H NMR spectrum

(CDCl<sub>3</sub>), δ, ppm (*J*, Hz): 1.35 s (6H, 2 CH<sub>3</sub>), 1.42 s (6H, 2 CH<sub>3</sub>), 3.44 t (2H, C<sup>6+6</sup>H<sub>a</sub>, *J* = 9.1, 6.9), 3.51 d (2H, C<sup>6+6</sup>H<sub>b</sub>, *J* = 10.7, 7.0), 3.72 t (2H, C<sup>5+5</sup>H<sub>a</sub>, *J* = 8.0, 6.2), 4.00 d (2H, C<sup>5+5</sup>H<sub>b</sub>, *J* = 8.2, 6.1), 4.08 dt (4H, C<sup>7+10</sup>H<sub>a</sub>, *J* = 11.8, 7.5), 4.15 dd (4H, C<sup>7+10</sup>H<sub>b</sub>, *J* = 11.1, 5.8), 4.24–4.29 m (1H, C<sup>4+4</sup>H), 5.69–5.81 m (2H, C<sup>8</sup>H, C<sup>9</sup>H). <sup>13</sup>C NMR spectrum (CDCl<sub>3</sub>), δ<sub>c</sub>, ppm: 25.28 (CH<sub>3</sub>), 26.44 (CH<sub>3</sub>), 64.23 (C<sup>5+5</sup>), 66.62 (C<sup>6+6</sup>), 71.35 (C<sup>7+10</sup>), 73.69 (C<sup>4+4</sup>), 109.44 (C<sup>2+2</sup>), 127.32 (C<sup>8</sup>), 130.55 (C<sup>9</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 316 (≤1) [M]<sup>+</sup>, 300 (70), 215 (50), 101 (100), 73 (20), 43 (70).

**4-({(2Z)-4-(allyloxy)-but-2-en-1-yl}oxy)methyl]-2,2-dimethyl-1,3-dioxolane 11.** Yield (11) 40%, bp = 99–101°C (4 mm Hg). <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>), δ, ppm (*J*, Hz): 1.41 t (3H, CH<sub>3</sub>, *J* = 7.7), 1.45 t (3H, CH<sub>3</sub>, *J* = 7.5), 3.45 t (1H, C<sup>6</sup>H<sub>a</sub>, *J* = 8.9, 5.9), 3.54 d (1H, C<sup>6</sup>H<sub>b</sub>, *J* = 10.0), 3.74 t (1H, C<sup>5</sup>H<sub>a</sub>, *J* = 8.0, 6.0), 4.11 d (1H, C<sup>5</sup>H<sub>b</sub>, *J* = 8.2), 3.72 t (1H, C<sup>11</sup>H<sub>a</sub>, *J* = 10.3, 5.8), 4.06 d (3H, C<sup>11</sup>H<sub>b</sub>, *J* = 5.9), 4.09 d (2H, C<sup>7</sup>H<sub>2</sub>, *J* = 7.7), 4.17 t (2H, C<sup>10</sup>H<sub>2</sub>, *J* = 10.4, 5.9), 4.25–4.29 m (1H, C<sup>4</sup>H), 5.18 d (1H, C<sup>13</sup>H<sub>a</sub>, *J* = 1.3, 10.4), 5.26 d (1H, C<sup>13</sup>H<sub>b</sub>, *J* = 15.0), 5.83–5.93 m (1H, C<sup>12</sup>H), 5.70–5.81 m (2H, C<sup>8</sup>H, C<sup>9</sup>H). <sup>13</sup>C NMR spectrum (CDCl<sub>3</sub>), δ<sub>c</sub>, ppm: 25.31 (CH<sub>3</sub>), 26.68 (CH<sub>3</sub>), 63.84 (C<sup>10</sup>), 65.30 (C<sup>5</sup>), 67.02 (C<sup>6</sup>), 67.77 (C<sup>7</sup>), 69.32 (C<sup>11</sup>), 71.55 (C<sup>4</sup>), 107.50 (C<sup>2</sup>), 122.92 (C<sup>13</sup>), 127.93 (C<sup>9</sup>), 131.02 (C<sup>8</sup>). 132.53 (C<sup>12</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 242 (≤3) [M]<sup>+</sup>, 300 (70), 275 (60), 215 (35), 145 (60), 101 (100), 73 (34), 43 (50).

**4-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxolane 15.** ЯМР спектр соединения описан в работе [25]. Yield (15) 90%, bp = 138°C (5 mm Hg). Mass spectrum *m/z* (*I*<sub>rel</sub>, %): 222 (≤1) [M]<sup>+</sup>, 207 (27), 164 (34), 101 (41), 91 (100), 43 (23).

**4-[(2-chloromethyl-benzyloxy)methyl]-2,2-dimethyl-1,3-dioxolane 16.** Yield (16) 90%, bp = 138°C (5 mm Hg). <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>), δ, ppm (*J*, Hz): 1.33 t (3H, CH<sub>3</sub>, *J* = 7.5), 1.41 t (3H, CH<sub>3</sub>, 6.8), 3.49 t (1H, C<sup>6</sup>H<sub>a</sub>, *J* = 11.5), 3.54 d (1H, C<sup>6</sup>H<sub>b</sub>, *J* = 11.2), 3.67 t (1H, C<sup>5</sup>H<sub>a</sub>, *J* = 9.6), 3.78 d (1H, C<sup>5</sup>H<sub>b</sub>, *J* = 10.0), 4.45–4.82 m (1H, C<sub>4</sub>H), 4.89 (s, 1H, C<sup>8</sup>H<sub>a</sub>), 4.91 (s, 1H, C<sup>8</sup>H<sub>a</sub>), 7.07–7.16 m (4H, 4 CH). <sup>13</sup>C NMR spectrum, δ<sub>c</sub>, ppm: 25.47 (CH<sub>3</sub>), 26.54 (CH<sub>3</sub>), 47.13 (C<sup>8</sup>H<sub>2</sub>), 66.43 (C<sup>5</sup>H<sub>2</sub>), 67.83 (C<sup>6</sup>H<sub>2</sub>), 68.37 (C<sup>7</sup>H<sub>2</sub>), 68.28 (C<sup>4</sup>H), 105.29 (C<sup>2</sup>), 127.07–139.61 (Ph). Масс-спектр *m/z* (*I*<sub>rel</sub>, %): 270/272 (≤1) [M]<sup>+</sup>, 255/257 (25/5), 101 (40), 73 (56), 91 (70), 77 (100), 41 (30).

**Synthesis of compounds 7–9 and 12.** Compounds 7–9 and 12 were obtained similarly to the procedure [25–27] using chloroform, 50% alkali solution, and catamine AB phase transfer catalyst.

**4-[(2,2-dichlorocyclopropyl)methoxy]-methyl]-2,2-dimethyl-1,3-dioxolane 7.** Yield (7) 70%, bp = 74–76°C (8 mm Hg). <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>), δ, ppm (*J*, Hz): 0.95–0.104 m (1H, C<sup>8</sup>H), 1.37

t (3H, CH<sub>3</sub>, *J* = 7.0), 1.43 t (3H, CH<sub>3</sub>, 6.8), 1.62 t (1H, C<sup>9</sup>H<sub>a</sub>, *J* = 5.3), 1.68 d (1H, C<sup>9</sup>H<sub>b</sub>, *J* = 5.4), 3.45 t (1H, C<sup>7</sup>H<sub>a</sub>, *J* = 11.0, 7.0), 3.57 d (1H, C<sup>7</sup>H<sub>b</sub>, *J* = 11.2), 3.61 t (1H, C<sup>6</sup>H<sub>a</sub>, *J* = 9.0, 7.0), 3.69 d (1H, C<sup>6</sup>H<sub>b</sub>, *J* = 8.9), 3.84 d (1H, C<sup>5</sup>H<sub>a</sub>, *J* = 6.0), 4.02 t (1H, C<sup>5</sup>H<sub>b</sub>, *J* = 6.7), 4.33–4.38 m (1H, C<sup>4</sup>H). <sup>13</sup>C NMR spectrum, δ<sub>c</sub>, ppm: 24.52 (CH<sub>2</sub>), 25.46 (CH<sub>3</sub>), 27.34 (CH<sub>3</sub>), 28.49 (CH), 61.03 (C), 67.83 (CH<sub>2</sub>), 68.58 (CH<sub>2</sub>), 69.42 (CH<sub>2</sub>), 69.78 (CH), 108.96 (C). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 225/227/229 (≤3) [M]<sup>+</sup>, 219/221 (40/15), 145 (45), 115/117 (30/8), 101 (100), 89/91 (60/35), 43 (80).

**4-({[2,2-dichloro-3-(chloromethyl)-cyclopropyl]methoxy}methyl)-2,2-dimethyl-1,3-dioxolane 8.** Yield (8) 50%, bp = 88–90°C (8 mm Hg). <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>), δ, ppm (*J*, Hz): 1.36 t (3H, CH<sub>3</sub>, *J* = 7.0), 1.41 t (3H, CH<sub>3</sub>, *J* = 6.8), 1.54–1.58 m (1H, C<sup>8</sup>H), 1.78–1.85 m (1H, C<sup>9</sup>H), 3.46 t (1H, C<sup>7</sup>H<sub>a</sub>, *J* = 9.0), 3.51 d (1H, C<sup>7</sup>H<sub>b</sub>, *J* = 9.3), 3.63 t (1H, C<sup>10</sup>H<sub>a</sub>, *J* = 9.2), 3.71 d (1H, C<sup>10</sup>H<sub>b</sub>, *J* = 8.8), 3.88 d (1H, C<sup>6</sup>H<sub>a</sub>, *J* = 6.5), 3.93 t (1H, C<sup>6</sup>H<sub>b</sub>, *J* = 6.6), 4.04 d (1H, C<sup>5</sup>H<sub>a</sub>, *J* = 6.8), 4.07 t (1H, C<sup>5</sup>H<sub>b</sub>, *J* = 6.5), 4.28–4.35 m (1H, C<sup>4</sup>H). <sup>13</sup>C NMR spectrum, δ<sub>c</sub>, ppm: 24.48 (CH<sub>3</sub>), 25.49 (CH<sub>3</sub>), 34.87 (C<sup>9</sup>H), 36.39 (C<sup>8</sup>H), 43.42 (C<sup>10</sup>H<sub>2</sub>), 63.06 (C), 67.86 (C<sup>6</sup>H<sub>2</sub>), 68.73 (C<sup>7</sup>H<sub>2</sub>), 69.42 (C<sup>5</sup>H<sub>2</sub>), 71.74 (C<sup>4</sup>H), 108.69 (C<sup>2</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 304/306/308 (≤2) [M]<sup>+</sup>, 269/271/273 (35/15/4), 219/221 (60/45), 145/65, 101/100, 89/91 (30/15), 41 (70).

**4,4-[(3,3dichlorocyclopropane-1,2-diyl)bis(methyleneoxymethylene)]bis(2,2-dimethyl-1,3-dioxolane) 9.** Yield (9) 60%, bp = 102–104°C (5 mm Hg). <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>), δ, ppm (*J*, Hz): 1.29 t (3H, CH<sub>3</sub>, *J* = 6.9), 1.34 t (3H, CH<sub>3</sub>, *J* = 6.7), 2.24 dt (2H, 2 C<sup>8+9</sup>H, *J* = 5.9, 8.9), 3.39 t (2H, 2 C<sup>7+10</sup>H<sub>a</sub>, *J* = 10.9), 3.42 d (2H, 2 C<sup>7+10</sup>H<sub>b</sub>, *J* = 10.2), 3.56 t (2H, 2 C<sup>6+6</sup>H<sub>a</sub>, *J* = 9.6), 3.63 d (2H, 2 C<sup>6+6</sup>H<sub>b</sub>, *J* = 8.2), 3.82 d (2H, 2 C<sup>5+5</sup>H<sub>a</sub>, *J* = 6.4), 4.00 t (2H, 2 C<sup>5+5</sup>H<sub>b</sub>, *J* = 6.6), 4.45–4.60 m (2H, 2 C<sup>4+4</sup>H). <sup>13</sup>C NMR spectrum, δ<sub>c</sub>, ppm: 25.45 (CH<sub>3</sub>), 26.30 (CH<sub>3</sub>), 34.76 (2 C<sup>8+9</sup>H), 64.55 (C), 67.93 (2 C<sup>5+5</sup>H<sub>2</sub>), 68.81 (2 C<sup>7+10</sup>H<sub>2</sub>), 72.66 (2 C<sup>6+6</sup>H<sub>2</sub>), 72.75 (2 C<sup>4+4</sup>H), 106.44 (C). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 400/402/404 (≤10) [M]<sup>+</sup>, 384/386/388 (30/14/6), 298/300/302 (40/22/12), 145/40, 115/117 (32/11), 101/100, 89/91 (80/30), 43 (80), 41 (50).

**4-{{[2,2-dichloro-3-(chloromethyl)-cyclopropyl]methoxy}methyl}-2,2-dimethyl-1,3-dioxolane 12.** Yield (12) 50%, bp = 134–136°C (2 mm Hg). <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>), δ, ppm (*J*, Hz): 0.90–1.01 m (1H, C<sup>12</sup>H), 1.26 t (3H, CH<sub>3</sub>, *J* = 6.4), 1.31 t (3H, CH<sub>3</sub>, *J* = 6.3), 1.57 t (1H, C<sup>13</sup>H<sub>a</sub>, *J* = 6.9), 1.62 d (1H, C<sup>13</sup>H<sub>b</sub>, *J* = 5.9), 2.05 qu (1H, C<sup>8</sup>H, *J* = 9.7), 2.23 qu (1H, C<sup>9</sup>H, *J* = 9.9), 3.56–3.61 m (4H, 2 C<sup>7+10</sup>H<sub>2</sub>), 3.66 t (1H, C<sup>11</sup>H<sub>a</sub>, *J* = 10.0), 3.73 d

(1H, C<sup>11</sup>H<sub>b</sub>, *J* = 9.9), 3.85 d (1H, C<sub>6</sub>H<sub>a</sub>, *J* = 7.9), 4.00 t (1H, C<sup>6</sup>H<sub>b</sub>, *J* = 6.9), 4.22 d (1H, C<sup>5</sup>H<sub>a</sub>, *J* = 6.9), 4.25 t (1H, C<sup>5</sup>H<sub>b</sub>, *J* = 7.8), 4.42–4.63 m (1H, C<sup>4</sup>H). <sup>13</sup>C NMR spectrum, δ<sub>C</sub>, ppm: 24.44 (C<sup>13</sup>H<sub>2</sub>), 25.45 (CH<sub>3</sub>), 26.30 (CH<sub>3</sub>), 28.56 (C<sup>12</sup>H), 35.39 (2 C<sup>8+9</sup>H), 61.20 (C), 63.91 (C), 67.58 (C<sup>5</sup>H<sub>2</sub>), 67.92 (C<sup>10</sup>H<sub>2</sub>), 69.34 (C<sup>11</sup>H<sub>2</sub>), 70.62 (C<sup>6</sup>H<sub>2</sub>), 71.28 (C<sup>7</sup>H<sub>2</sub>), 72.55 (C<sup>4</sup>H), 110.29 (C). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 408/410/412/414 (≤5) [M]<sup>+</sup>, 393/395/397/399 (35/40/16/9/3), 372/374/376/378 (17/25/8/3), 298/300/302 (60/35/18), 154/156/158 (55/36/14), 115/117 (32/11), 101/100, 89/91 (70/25), 41 (70).

#### Assessment of the cytotoxicity of the substances *in vitro*

The cytotoxicity of the substances was studied using SH-SY5Y (human neuroblastoma), A549 (human lung adenocarcinoma), and MCF-7 (adenocarcinoma of the human mammary gland ducts) tumor cell lines and the HEK293 (immortalized human embryonic kidney cells) normal cell line, which were obtained from the Russian collection of cell cultures (Institute of Cytology, Russian Academy of Sciences, St. Petersburg). HEK293 cells (25 × 10<sup>3</sup> cells per well), SH-SY5Y (50 × 10<sup>3</sup> cells per well), MCF-7 (12 × 10<sup>3</sup> cells per well), and A549 (10 × 10<sup>3</sup> cells per well) were seeded in 96-well plates in 100 μL of DMEM medium containing 10% FBS (*Gibco*, USA), 2 mM L-glutamine (*PanEco*, Russia), and 50 μg/mL gentamicin (*Biolot*, Russia). After 24 h, the candidate substances were added to the cells at concentrations of 1, 10, and 100 μM in 0.1% DMSO, followed by incubation for 48 h at 37°C in 5% CO<sub>2</sub>. The cytotoxic properties of the substances were then assessed using PrestoBlue® vital dye according to the manufacturer's protocol (*Invitrogen*, USA), and fluorescence was detected using a 2300 EnSpire® Multimode Plate Reader (*Perkin Elmer*, USA). The IC<sub>50</sub> value (substance concentration at which 50% inhibition of cell viability is observed) was calculated using the GraphPad Prism 4.0 program (*GraphPad Software Inc.*, USA).

The selectivity index (SI) of each substance was determined to reveal the possible selectivity of its cytotoxic effects against tumor cells, i.e., its potential antitumor properties. The HEK293 cell line served as control cells of normal origin, and the SI of the substance was calculated as the ratio of the IC<sub>50</sub> value in HEK293 cells to the IC<sub>50</sub> in tumor cells.

Statistical analysis of the obtained data was carried out using the standard Statistica 6.1 software package (*StatSoft Inc.*, USA). The results were presented as the arithmetic mean of 3 independent experiments (*M*), including the standard error of the mean (±*m*). Analysis of variance using the Dunnett's test was used to determine the significance of differences in the IC<sub>50</sub> values of the substances between cells of normal and tumor origin.

## RESULTS AND DISCUSSION

The *O*-alkylation of 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane **1** with allyl chloride **2** and *cis*-1,4-dichlorobutene-2 **3** resulted in the corresponding ethers **4–6** being obtained in yields of 60–90%. The subsequent dichlorocarbenation of compounds **4–6** according to a previously reported procedure [25–27] synthesized products **7–9** in yields of 50–70%, which contained heterocyclic and carbocyclic fragments (Scheme 1).



Chloromethyl derivative **5** was used for the *O*-alkylation of allyl alcohol **10**, which produced compound **11** with two double bonds in a yield of 40%. Its exhaustive dichlorocarbenation led to diester **12** (50% yield), which contained one 1,3-dioxolane and two *gem*-dichlorocyclopropane fragments (Scheme 1).

Competitive kinetics was used to determine the relative reactivity of chlorides **2** and **3** in the reaction with 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane **1**. Judging by the rate of product accumulation of **4** and **5**, allyl chloride **2** was 2 times more active than *cis*-1,4-dichlorobutene-2 **3**. By considering the number of reaction centers, the CH<sub>2</sub>Cl group in olefin **2** is 4 times more active than the analogous group in compound **3**, which is likely due to the chlorine atoms in position 1 and 4 making it difficult for the bulky alcoholate to approach the CH<sub>2</sub>–Cl group. This assumption was confirmed by the competitive *O*-alkylation of 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane **1** with benzyl chloride **13** and 1,2-dichloromethylbenzene **14** (Scheme 2) resulting in the accumulation of esters **15** and **16**, which means that monochloride **13** is also 1.5 times more active than dichloride **14**.

The structures of **4–9**, **11**, **12**, **15**, and **16** were elucidated by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy and chromatomass spectrometry.

The initial biological screening of new substances, regardless of their intended use, is the assessment of their basic cytotoxicity *in vitro*, which is defined as the negative effect of chemical compounds on the vital functions of the cell, e.g., damage to cell membranes, disruption of the metabolic activity of cells, changes in the processes of cell division, and protein synthesis. Continuous cell lines of various origins are used in this analysis.<sup>1</sup> The *in vitro* cytotoxicity assessment of polycyclic compounds **7–9** and **12** was performed using normal (HEK293) and tumor (SH-SY5Y, MCF-7, A549) cell lines to reveal both possible cytotoxicity and also the selectivity of their action, e.g., organ specificity or antitumor activity. The PrestoBlue® test used for

<sup>1</sup> Vakhitova Yu.V., Tselousova O.S. *Kletochnye mehanizmy toksichnosti ksenobiotikov (Cellular mechanisms of xenobiotic toxicity)*. Textbook. 2nd ed., revised and add. Ufa: BSPU, 2015. 104 p.

**Scheme 1.** Synthesis of 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane ethers **1**.**Scheme 2.** Alkylation of 2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane **1** by chlorides **13** and **14**.






these screens allows for the detection of changes in the metabolic activity of cells against the background of the substances under study, which acts as a proxy for cell viability.

From the obtained data (see Table) only compound **12** ( $IC_{50} < 100 \mu M$ ) exhibited moderate cytotoxic activity against the HEK293, SH-SY5Y, MCF-7, and A549 cell lines. Substances **8** and **9** did not affect the viability of cell lines in the concentration range of 1–100  $\mu M$ . The activity of the tricyclic compound **12** against the HEK293, SH-SY5Y, and A549 cell lines is in agreement with the previously studied corresponding bicyclic

compound 8,8-dichloro-4-isopropyl-3,5-dioxabicyclooctane [28] but is inferior to the cinnamaldehyde derivative 2-(2,2-dichloro-3-phenylcyclopropyl)-1,3-dioxolane. No pronounced selectivity in the cytotoxic effects of compound **12** was observed for a particular tumor cell line (the maximum SI value was 1.18 for A549 cells).

Considering the structure of the synthesized substances and their cytotoxicity we assumed that the toxicity of compound **12** was due to an increase in the amount of gem-dichlorocyclopropane fragments compared with compound **8**. This is confirmed by

Influence of compounds on cell viability (48 h,  $M \pm m$ )

Formula and compound number	$IC_{50}, \mu M$			
	Hek293	SH-SY5Y	MCF-7	A549
 8	>100	>100	>100	>100
 9	>100	>100	>100	>100
 12	$57.4 \pm 4.3$	$86.2 \pm 2.1$ SI = 0.67**	$72.7 \pm 1.7$ SI = 0.79**	$48.8 \pm 2.3$ SI = 1.18**
 *	$73.0 \pm 5.7$	$93.2 \pm 9.6$ SI = 0.78**	$21.0 \pm 1.8$ SI = 3.45**	$56.0 \pm 4.2$ SI = 1.30**
 *	$48.0 \pm 3.1$	$58.67 \pm 3.6$ SI = 0.82**	$27.6 \pm 0.7$ SI = 1.74**	$33.7 \pm 2.8$ SI = 1.42**

Note: The results are presented as the arithmetic mean of three independent experiments ( $M$ ), indicating the standard error of the mean ( $\pm m$ ).

\* Results from work [10].

\*\* Selectivity Index (SI) is the ratio of the  $IC_{50}$  of the test compound for control HEK293 cells to  $IC_{50}$  for tumor cells.

comparing **12** with substances reported in [28]; the presence of the *gem*-dichlorocyclopropane group with the 1,3-dioxolane radical through oxygen in **12** reduces its negative impact on cell viability.

Thus, the analysis of compound **12** showed that an increase in the amount of *gem*-dichlorocyclopropane fragments caused cytotoxicity resulting from a change in the metabolic activity of the studied cells. The exact mechanism causing this effect is currently unknown and is the subject of our current research. Our results elaborate our understanding of the relationship of the structure of heterocyclic compounds containing *gem*-dichlorocyclopropane groups and/or 1,3-dioxolane radicals and their subsequent cytotoxic activity. Compounds **8**, **9**, and **12** may be promising candidates for the study of other types of biological activity.

## CONCLUSIONS

Ethers containing *gem*-dichlorocyclopropane and 1,3-dioxolane fragments were synthesized in the presence of a catamine AB catalyst. The structures of the obtained substances were confirmed using mass spectrometry and NMR spectroscopy. Only one of several obtained compounds, 4-{{[(2,2-dichloro-3-{{[(2,2-dichlorocyclopropyl)methoxy]methyl}} cyclopropyl)methoxy]methyl}-2,2-dimethyl-1,3-dioxolane, had

a negative impact on the metabolic activity of cells, regardless of their normal or tumor origin. Our analysis of the obtained data allowed us to establish that the toxic properties manifest due to an increase in the amount of *gem*-dichlorocyclopropane fragments in the candidate molecule and, subsequently, the cell.

## Acknowledgments

The study was supported by the Ministry of Science and Higher Education of the Russian Federation, the agreement No. 075-15-2020-900 within the framework of the WCRC development program.

## Authors' contribution

**Sh.Sh. Dzhumaev** – conducting research, reviewing publications on the topic of articles;

**Y.G. Borisova** – collecting and processing the material, writing the text of the article;

**G.Z. Raskil'dina** – collecting and processing the material, statistical processing;

**U.Sh. Kuzmina** – conducting biological research;

**R.R. Daminev** – consultation on planning, methodology and research implementation;

**S.S. Zlotskii** – development of the concept of the study, critical revision with the introduction of valuable intellectual content.

The authors declare no conflicts of interest.

## REFERENCES

1. Yakovenko E.A., Raskil'dina G.Z., Mryasova L.M., Zlotsky S.S. Synthesis and herbicidal activity of some esters and amides that include saturated oxygen-containing heterocycles. *Khimika i Tekhnologiya Organicheskikh Veshchestv = Chemistry and Technology of Organic Substances*. 2019;3(11):4–13 (in Russ.).
2. Stanislawski P.C., Willis A.C., Banwell M.G. *gem*-Dihalocyclopropanes as building blocks in natural-product synthesis: enantioselective total syntheses of *ent*-erythramine and 3-*epi*-erythramine. *Chem. Asian J.* 2007;2(9):1127–1136. <https://doi.org/10.1002/asia.200700155>
3. Sakhabutdinova G.N., Raskil'dina G.Z., Meshcheryakova S.A., Shumadalova A.V., Bortsova Yu.L., Kuzmina U.Sh., Zlotsky S.S., Sultanova R.M. Antioxidant and cytotoxic activity of a series of *O*- and *S*-containing macrocycles. *Izv. Vyssh. Uchebn. Zaved. Khim. Khim. Tekhnol. = Russ. J. Chem. & Chem. Tech.* 2020;63(3):82–88 (in Russ.). <https://doi.org/10.6060/ivkkt.20206303.6118>
4. Varfolomeev S.D., Nikiforov G.A., Vol'eva V.B., et al. Octane-increasing additive to petrol: RF Pat. 2365617. Publ. 27.08.2009. (in Russ.).
5. Küçük H.B., Yusufoglu A.S., Mataraci E., Döşler S. Synthesis and biological activity of new 1,3-dioxolanes as potential antibacterial and antifungal compounds. *Molecules*. 2011;16(8):6806–6815. <https://doi.org/10.3390/molecules16086806>

## СПИСОК ЛИТЕРАТУРЫ

1. Яковенко Е.А., Раскильдина Г.З., Мрясова Л.М., Злотский С.С. Получение и гербицидная активность некоторых сложных эфиров и амидов, включающих насыщенные кислородсодержащие гетероциклы. *Химия и технология органических веществ*. 2019;3(11):4–13.
2. Stanislawski P.C., Willis A.C., Banwell M.G. *gem*-Dihalocyclopropanes as building blocks in natural-product synthesis: enantioselective total syntheses of *ent*-erythramine and 3-*epi*-erythramine. *Chem. Asian J.* 2007;2(9):1127–1136. <https://doi.org/10.1002/asia.200700155>
3. Сахабутдинова Г.Н., Раскильдина Г.З., Мещерякова С.А., Шумадалова А.В., Бортсова Ю.Л., Кузьмина У.Ш., Злотский С.С., Султанова Р.М. Антиоксидантная и цитотоксическая активность ряда *O*- и *S*-содержащих макроциклов. *Изв. вузов. Химия и хим. технология*. 2020;63(3):82–88. <https://doi.org/10.6060/ivkkt.20206303.6118>
4. Варфоломеев С.Д., Никифоров Г.А., Вольева В.Б. и др. Октаноповышающая добавка к бензину: пат. 2365617 РФ. Заявка 2008121078/04; заявл. 28.05.2008; опубл. 27.08.2009. Бюл. № 24.
5. Küçük H.B., Yusufoglu A.S., Mataraci E., Döşler S. Synthesis and biological activity of new 1,3-dioxolanes as potential antibacterial and antifungal compounds. *Molecules*. 2011;16(8):6806–6815. <https://doi.org/10.3390/molecules16086806>

6. Genta M.T., Villa C., Mariani E., Loupy A., Petit A., Rizzetto R., Mascarotti A., Morini, F., Ferro M. Microwave-assisted preparation of cyclic ketals from a cineole ketone as potential cosmetic ingredients: solvent-free synthesis, odour evaluation, *in vitro* cytotoxicity and antimicrobial assays. *Int. J. Pharm.* 2002;231(1):11–20. [https://doi.org/10.1016/S0378-5173\(01\)00821-3](https://doi.org/10.1016/S0378-5173(01)00821-3)
7. Raskil'dina G.Z., Sakhabutdinova G.N., Purygin P.P., Bondareva N.A., Borisova Yu.G., Zlotsky S.S. Anticoagulant and antiaggregatory activities of a series of substituted 1,3-dioxacycloalkanes and *O*-, *S*-containing macrocycles. *Butlerovskie Soobshcheniya*. 2021;65(1):53–58 (in Russ.). Available from URL: <https://butlerov.com/files/reports/2021/vol65/1/53/21-65-1-53-.pdf>
8. Ovsyannikova M.N., Vol'eva V.B., Belostotskaya I.S., et al. Antibacterial activity of substituted 1,3-dioxolanes. *Pharm. Chem. J.* 2013;47(3):142–145. <https://doi.org/10.1007/s11094-013-0913-6>
9. Kailania M.H., Al-Bakrib A.G., Saadeha H., Al-Hiari Y.M. Preparation and Antimicrobial Screening of Novel 2,2-dichloro-cyclopropane-*cis*-dicarbamates and Comparison to their Alkane and *cis*-Alkene Analogs. *Jordan J. Chem.* 2012;7(3):239–252.
10. Soldatenkov A.T., Anh L.T., Hieu T.H., Nikitina E.V., Alarcon H.R. *Prirodnye biologicheski aktivnye veshchestva (Natural biologically active substances)*. Hanoi: Znaniya; 2016. 376 p. (in Russ.).
11. Ozkanli F, Güney A, Çalış U, Uzbay T. Synthesis and anticonvulsant activity of some new dioxolane derivatives. *Arzneimittel-Forschung*. 2003;53(11):758–762. <https://doi.org/10.1002/chin.200409098>
12. Schmidt M., Ungvári J., Glöde J., Dobner B., Langner A. New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance. *Bioorg. Med. Chem.* 2007;15(6):2283–2297. <https://doi.org/10.1016/j.bmc.2007.01.024>
13. Nguyen-Ba N., Lee N., Chan L., Zacharie B. Synthesis and antiviral activities of *N*-9-oxypurine 1,3-Dioxolane and 1,3-oxathiolane nucleosides. *Bioorg. Med. Chem. Lett.* 2000;10(19):2223–2226. [https://doi.org/10.1016/S0960-894X\(00\)00452-2](https://doi.org/10.1016/S0960-894X(00)00452-2)
14. Bera S., Malik L., Bhat B., Carroll S.S., MacCoss M., Olsen D.B., Tomassini J.E., Eldrup A.B. Synthesis and evaluation of optically pure dioxolanes as inhibitors of hepatitis C virus RNA replication. *Bioorg. Med. Chem. Lett.* 2003;13(24):4455–4458. <https://doi.org/10.1016/j.bmcl.2003.09.008>
15. Zapata-Sudo G., Pontes L.B., Gabriel D., Mendes T.C.F., Ribeiro N.M., Pinto A.C., Trachez M.M., Sudo R.T. Sedative-hypnotic profile of novel isatin ketals. *Pharmacol. Biochem. Behav.* 2007;86(4):678–685. <https://doi.org/10.1016/j.pbb.2007.02.013>
16. Ramazanov D.N., Dzhumbe A., Nekhaev A.I., Samoilov V.O., Maximov A.L., Egorova E.V. Reaction between glycerol and acetone in the presence of ethylene glycol. *Pet. Chem.* 2015;55(2):140–145. <https://doi.org/10.1134/S0965544115020152>
17. Barbosa S.L., Lima P.C. Oxygenated biofuels: Synthesis of fatty acid solketal esters with a mixture of sulfonated silica and  $(Bu_4N)(BF_4^-)$  catalyst. *Catal. Commun.* 2019;120:76–79. <https://doi.org/10.1016/j.catcom.2018.12.005>
18. Sulistyo H., Huda E.N., Utami T.S., et al. Solketal Production by Glycerol Acetalization Using Amberlyst-15 Catalyst. *ASEAN J. Chem. Eng.* 2020;20(1):67–76. <https://doi.org/10.22146/ajche.52455>
6. Genta M.T., Villa C., Mariani E., Loupy A., Petit A., Rizzetto R., Mascarotti A., Morini, F., Ferro M. Microwave-assisted preparation of cyclic ketals from a cineole ketone as potential cosmetic ingredients: solvent-free synthesis, odour evaluation, *in vitro* cytotoxicity and antimicrobial assays. *Int. J. Pharm.* 2002;231(1):11–20. [https://doi.org/10.1016/S0378-5173\(01\)00821-3](https://doi.org/10.1016/S0378-5173(01)00821-3)
7. Раскильдина Г.З., Сахабутдинова Г.Н., Пурыгин П.П., Бондарева Н.А., Борисова Ю.Г., Злотский С.С. Антикоагуляционная и антиагрегационная активности ряда замещенных 1,3-диоксациклоалканов и *O*-, *S*-содержащих макроциклов. *Бутлеровские сообщения*. 2021;65(1):53–58. URL: <https://butlerov.com/files/reports/2021/vol65/1/53/21-65-1-53-.pdf>
8. Овсянникова М.Н., Вол'ева В.В., Белостотская И.С., et al. Antibacterial activity of substituted 1,3-dioxolanes. *Pharm. Chem. J.* 2013;47(3):142–145. <https://doi.org/10.1007/s11094-013-0913-6>
9. Kailania M.H., Al-Bakrib A.G., Saadeha H., Al-Hiari Y.M. Preparation and Antimicrobial Screening of Novel 2,2-dichloro-cyclopropane-*cis*-dicarbamates and Comparison to their Alkane and *cis*-Alkene Analogs. *Jordan J. Chem.* 2012;7(3):239–252
10. Солдатенков А.Т., Ань Л.Т., Хиэу Ч.Х., Никитина Е.В., Аларкон Х.Р. *Природные биологически активные вещества*. Ханой: Знания; 2016. 376 с.
11. Ozkanli F, Güney A, Çalış U, Uzbay T. Synthesis and anticonvulsant activity of some new dioxolane derivatives. *Arzneimittel-Forschung*. 2003;53(11):758–762. <https://doi.org/10.1002/chin.200409098>
12. Schmidt M., Ungvári J., Glöde J., Dobner B., Langner A. New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance. *Bioorg. Med. Chem.* 2007;15(6):2283–2297. <https://doi.org/10.1016/j.bmc.2007.01.024>
13. Nguyen-Ba N., Lee N., Chan L., Zacharie B. Synthesis and antiviral activities of *N*-9-oxypurine 1,3-Dioxolane and 1,3-oxathiolane nucleosides. *Bioorg. Med. Chem. Lett.* 2000;10(19):2223–2226. [https://doi.org/10.1016/S0960-894X\(00\)00452-2](https://doi.org/10.1016/S0960-894X(00)00452-2)
14. Bera S., Malik L., Bhat B., Carroll S.S., MacCoss M., Olsen D.B., Tomassini J.E., Eldrup A.B. Synthesis and evaluation of optically pure dioxolanes as inhibitors of hepatitis C virus RNA replication. *Bioorg. Med. Chem. Lett.* 2003;13(24):4455–4458. <https://doi.org/10.1016/j.bmcl.2003.09.008>
15. Zapata-Sudo G., Pontes L.B., Gabriel D., Mendes T.C.F., Ribeiro N.M., Pinto A.C., Trachez M.M., Sudo R.T. Sedative-hypnotic profile of novel isatin ketals. *Pharmacol. Biochem. Behav.* 2007;86(4):678–685. <https://doi.org/10.1016/j.pbb.2007.02.013>
16. Ramazanov D.N., Dzhumbe A., Nekhaev A.I., Samoilov V.O., Maximov A.L., Egorova E.V. Reaction between glycerol and acetone in the presence of ethylene glycol. *Pet. Chem.* 2015;55(2):140–145. <https://doi.org/10.1134/S0965544115020152>
17. Barbosa S.L., Lima P.C. Oxygenated biofuels: Synthesis of fatty acid solketal esters with a mixture of sulfonated silica and  $(Bu_4N)(BF_4^-)$  catalyst. *Catal. Commun.* 2019;120:76–79. <https://doi.org/10.1016/j.catcom.2018.12.005>
18. Sulistyo H., Huda E.N., Utami T.S., et al. Solketal Production by Glycerol Acetalization Using Amberlyst-15 Catalyst. *ASEAN J. Chem. Eng.* 2020;20(1):67–76. <https://doi.org/10.22146/ajche.52455>

19. Fatimah I., Sahroni I., Fadillah G., et al. Glycerol to Solketal for Fuel Additive: Recent Progress in Heterogeneous Catalysts. *Energies*. 2019;12(15):2872. <https://doi.org/10.3390/en12152872>
20. Ilgen O., Yerlikaya S., Akyurek F.O. Synthesis of Solketal from Glycerol and Acetone over Amberlyst-46 to Produce an Oxygenated Fuel Additive. *Period. Polytech. Chem. Eng.* 2017;61(2):144–148. <https://doi.org/10.3311/PPch.8895>
21. Dmitriev G.S., Zanaveskin L.N., Terekhov A.V., et al. Technologies for processing of crude glycerol from biodiesel production: synthesis of solketal and its hydrolysis to obtain pure glycerol. *Russ. J. Appl. Chem.* 2018;91:1478–1485. <https://doi.org/10.1134/S1070427218090100>
22. Behr A., Eilting J., Irawadi K., Leschinski J., Lindner F., et al. Improved utilisation of renewable resources: New important derivatives of glycerol. *Green Chem.* 2008;10(1):13–30. <https://doi.org/10.1039/B710561D>
23. Raskil'dina G.Z., Valiev V.F., Sultanova R.M., Zlotsky S.S. Selective functionalization of the primary hydroxy group in triols. *Russ. J. Appl. Chem.* 2015;88(10):1599–1604. <https://doi.org/10.1134/S1070427215100079>  
[Original Russian Text: Raskil'dina G.Z., Valiev V.F., Sultanova R.M., Zlotsky S.S. Selective functionalization of the primary hydroxy group in triols. *Zhurnal Prikladnoi Khimii*. 2015;88(10):1414–1419 (in Russ.).]
24. Valiev V.F., Raskildina G.Z., Mudrik T.P., Bogomazova A.A., Zlotsky S.S. Synthesis of polyfunctional vicinal glycoles. *Bashkir. khim. zh. = Bashkir Chem. J.* 2014;21(3):25–27 (in Russ.). Available from URL: [http://bcj.rusoil.net/files/slider/BCJ\\_3\\_2014.pdf](http://bcj.rusoil.net/files/slider/BCJ_3_2014.pdf)
25. Thankachan A.P., Sindhu K.S., Krishnan K.K., Anilkumar G. Recent advances in the syntheses, transformations and applications of 1,1-dihalocyclopropanes. *Org. Biom. Chem.* 2015;13(33):8780–8802. <https://doi.org/10.1039/C5OB01088H>
26. Fedoryński M. Syntheses of *gem*-Dihalocyclopropanes and Their Use in Organic Synthesis. *Chem. Rev.* 2003;103(4):1099–1132. <https://doi.org/10.1021/cr0100087>
27. Østby R.B., Didriksen T., Antonsen S.G., Nicolaisen S.S., Stenstrøm Y. Two-phase dibromocyclopropanation of unsaturated alcohols using flow chemistry. *Molecules*. 2020;25(10):2364–2376. <https://doi.org/10.3390/molecules25102364>
28. Raskil'dina G.Z., Kuzmina U.S., Dzhumaev S.S., et al. Synthesis and cytotoxic properties of some cyclic acetals of diols and their dichlorocyclopropyl derivatives. *Russ. Chem. Bull.* 2021;70:475–478. <https://doi.org/10.1007/s11172-021-3111-9>  
[Original Russian Text: Raskil'dina G.Z., Kuzmina U.S., Dzhumaev Sh.Sh., Borisova Yu.G., Ishmetova D.V., Vakhitova Yu.V., Zlotsky S.S. Synthesis and cytotoxic properties of some cyclic acetals of diols and their dichlorocyclopropyl derivatives. *Izv. Akad. Nauk. Ser. Khim.* 2021;70(3):475–478 (in Russ.).]
19. Fatimah I., Sahroni I., Fadillah G., et al. Glycerol to Solketal for Fuel Additive: Recent Progress in Heterogeneous Catalysts. *Energies*. 2019;12(15):2872. <https://doi.org/10.3390/en12152872>
20. Ilgen O., Yerlikaya S., Akyurek F.O. Synthesis of Solketal from Glycerol and Acetone over Amberlyst-46 to Produce an Oxygenated Fuel Additive. *Period. Polytech. Chem. Eng.* 2017;61(2):144–148. <https://doi.org/10.3311/PPch.8895>
21. Dmitriev G.S., Zanaveskin L.N., Terekhov A.V., et al. Technologies for processing of crude glycerol from biodiesel production: synthesis of solketal and its hydrolysis to obtain pure glycerol. *Russ. J. Appl. Chem.* 2018;91:1478–1485. <https://doi.org/10.1134/S1070427218090100>
22. Behr A., Eilting J., Irawadi K., Leschinski J., Lindner F., et al. Improved utilisation of renewable resources: New important derivatives of glycerol. *Green Chem.* 2008;10(1):13–30. <https://doi.org/10.1039/B710561D>
23. Raskil'dina G.Z., Valiev V.F., Sultanova R.M., Zlotsky S.S. Selective functionalization of the primary hydroxy group in triols. *Russ. J. Appl. Chem.* 2015;88(10):1599–1604. <https://doi.org/10.1134/S1070427215100079>
24. Валиев В.Ф., Раскильдина Г.З., Мудрик Т.П., Богомазова А.А., Злотский С.С. Синтез полифункциональных вицинальных гликолов. *Баш. хим. журн.* 2014;21(3):25–27. [http://bcj.rusoil.net/files/slider/BCJ\\_3\\_2014.pdf](http://bcj.rusoil.net/files/slider/BCJ_3_2014.pdf)
25. Thankachan A.P., Sindhu K.S., Krishnan K.K., Anilkumar G. Recent advances in the syntheses, transformations and applications of 1,1-dihalocyclopropanes. *Org. Biom. Chem.* 2015;13(33):8780–8802. <https://doi.org/10.1039/C5OB01088H>
26. Fedoryński M. Syntheses of *gem*-Dihalocyclopropanes and Their Use in Organic Synthesis. *Chem. Rev.* 2003;103(4):1099–1132. <https://doi.org/10.1021/cr0100087>
27. Østby R.B., Didriksen T., Antonsen S.G., Nicolaisen S.S., Stenstrøm Y. Two-phase dibromocyclopropanation of unsaturated alcohols using flow chemistry. *Molecules*. 2020;25(10):2364–2376. <https://doi.org/10.3390/molecules25102364>
28. Раскильдина Г.З., Кузьмина У.Ш., Джумаев Ш.Ш., Борисова Ю.Г., Вахитова Ю.В., Злотский С.С. Синтез и цитотоксические свойства некоторых циклических ацеталей диолов и их дихлорциклоопановых производных. *Изв. AH. Сер. хим.* 2021;70(3):475–478.

**About the authors:**

**Shahobiddin Sh. Dzhumaev**, Postgraduate Student, Department of General, Analytical and Applied Chemistry, Ufa State Petroleum Technological University (1, Kosmonavtov ul., Ufa, 450064, Russia). E-mail: shakhab2993@mail.ru. <https://orcid.org/0000-0002-1938-1478>

**Yulianna G. Borisova**, Cand. Sci. (Chem.), Teacher, Department of General, Analytical and Applied Chemistry, Ufa State Petroleum Technological University (1, Kosmonavtov ul., Ufa, 450064, Russia). E-mail: yulianna\_borisova@mail.ru. Scopus Author ID 56526865000, ResearcherID P-9744-2017, <https://orcid.org/0000-0001-6452-9454>

**Gul'nara Z. Raskil'dina**, Cand. Sci. (Chem.), Associate Professor, Department of General, Analytical and Applied Chemistry, Ufa State Petroleum Technological University (1, Kosmonavtov ul., Ufa, 450064, Russia). E-mail: graskildina444@mail.ru. Scopus Author ID 56069888400, ResearcherID F-1619-2017, <https://orcid.org/0000-0001-9770-5434>

**Ulyana Sh. Kuzmina**, Cand. Sci. (Biol.), Researcher, Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences (71, Oktyabrya pr., Ufa, 450054, Russia). E-mail: ulia-bio@yandex.ru. ResearcherID I-9754-2018, <https://orcid.org/0000-0001-7056-7895>

**Rustem R. Daminev**, Dr. Sci. (Eng.), Professor, Director of Branch in Sterlitamak, Ufa State Petroleum Technological University, Branch in Sterlitamak (2, Oktyabrya pr., Sterlitamak, 453118, Russia). E-mail: daminew@mail.ru. Scopus Author ID 15026168000, <https://orcid.org/0000-0001-8673-5240>

**Simon S. Zlotskii**, Dr. Sci. (Chem.), Professor, Head of the Department of General, Analytical and Applied Chemistry, Ufa State Petroleum Technological University (1, Kosmonavtov ul., Ufa, 450064, Russia). E-mail: nocturne@mail.ru. Scopus Author ID 6701508202, ResearcherID W-6564-2018, <https://orcid.org/0000-0001-6365-5010>

#### Об авторах:

**Джумаев Шахобиддин Шамсидинович**, аспирант кафедры общей, аналитической и прикладной химии, ФГБОУ ВО «Уфимский государственный нефтяной технический университет» (450064, Россия, г. Уфа, ул. Космонавтов, д. 1). E-mail: shakhob2993@mail.ru. <https://orcid.org/0000-0002-1938-1478>

**Борисова Юлианна Геннадьевна**, к.х.н. преподаватель кафедры общей, аналитической и прикладной химии, филиал ФГБОУ ВО «Уфимский государственный нефтяной технический университет» (450064, Россия, г. Уфа, ул. Космонавтов, д. 1). E-mail: yulianna\_borisova@mail.ru. Scopus Author ID 56526865000, ResearcherID P-9744-2017, <https://orcid.org/0000-0001-6452-9454>

**Раскильдина Гульнара Зинуровна**, к.х.н., доцент кафедры общей, аналитической и прикладной химии, ФГБОУ ВО «Уфимский государственный нефтяной технический университет» (450064, Россия, г. Уфа, ул. Космонавтов, д. 1). E-mail: graskildina444@mail.ru. Scopus Author ID 56069888400, ResearcherID F-1619-2017, <https://orcid.org/0000-0001-9770-5434>

**Кузьмина Ульяна Шавкатовна**, к.б.н., научный сотрудник, Институт биохимии и генетики УФИЦ РАН (450054, Россия, г. Уфа, пр. Октября, д. 71). E-mail: ulia-bio@yandex.ru. ResearcherID I-9754-2018, <https://orcid.org/0000-0001-7056-7895>

**Даминев Рустем Рифович**, д.т.н., профессор, директор филиала в г. Стерлитамак ФГБОУ ВО «Уфимский государственный нефтяной технический университет», филиал в г. Стерлитамак (453118, Россия, г. Стерлитамак, Октября пр-т, д. 2). E-mail: daminew@mail.ru. Scopus Author ID 15026168000. <https://orcid.org/0000-0001-8673-5240>

**Злотский Семен Соломонович**, д.х.н., заведующий кафедрой общей, аналитической и прикладной химии, ФГБОУ ВО «Уфимский государственный нефтяной технический университет» (450064, Россия, г. Уфа, ул. Космонавтов, д. 1). E-mail: nocturne@mail.ru. Scopus Author ID 6701508202, ResearcherID W-6564-2018, <https://orcid.org/0000-0001-6365-5010>

The article was submitted: February 16, 2021; approved after reviewing: March 10, 2021; accepted for publication: April 05, 2021.

Translated from Russian into English by H. Moshkov

Edited for English language and spelling by Enago, an editing brand of Crimson Interactive Inc.